Sab Biotherapeutics (SABS) traded down -1.76 % during a 24 hours period ending at 03:18 AM Central Europe on Wednesday 28th. One Sab Biotherapeutics stock can currently be bought for about USD 3.07 on popular exchanges. Current supply of Sab Biotherapeutics stocks is 91 mn. Sab Biotherapeutics has a current market capitalization of USD 253.4 mn and approximately USD 904.8 k worth of Sab Biotherapeutics was traded on exchanges in the last 24 hours. Since last month end, Sab Biotherapeutics has traded -13.22 % down. Simple moving average of last 200 days is at USD 3.69. The highest price of past 52 weeks was recorded at USD 5.15 on 03/12/2026. 52 weeks low was at USD 2.44 on 10/19/2026.
Here is how related stocks have performed in the past 24 hours:
Jena Acquisition Ii (JENA) traded flat 0 % and now trades at USD 10.42. Current market capitalisation for Jena Acquisition Ii is USD 301.9 mn.
Regional Management (RM) traded down -0.61 % and now trades at USD 32.89. Current market capitalisation for Regional Management is USD 302.1 mn. Current price/earnings ratio for Regional Management is 6.83.
Iv Acquisition (GSRF) traded flat 0 % and now trades at USD 10.28. Current market capitalisation for Iv Acquisition is USD 302 mn. Iv Acquisition has a current price to earnings ratio of 43.98.
Ni (NODK) traded down -0.6 % and now trades at USD 14.78. Current market capitalisation for Ni is USD 304 mn. Current price/earnings ratio for Ni is 39.71.
Benitec Biopharma (BNTC) traded down -0.69 % and now trades at USD 8.68. Current market capitalisation for Benitec Biopharma is USD 301.7 mn.
About Sab Biotherapeutics
SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company based in Sioux Falls, United States. The company’s mission is to harness the power of the body’s natural defense system to tackle the intricacies, rise, and mutations of human disease. They operate on Nasdaq and their website is www.sabbiotherapeutics.com .